TrialRadiation oncology (London, England)2021

Sintilimab, stereotactic body radiotherapy and granulocyte-macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial.

Jianjiao Ni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.